Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.35 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.35 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.35 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.34 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.32 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4990403 | 0.86 | ANPEP (0.36) | ANPEPSLC1A3SLC1A2HSP90AB1SLC1A1 | |
| SCHEMBL4989957 | 0.85 | GRIA2 (0.48) | ANPEPRNPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL4990096 | 0.84 | SLC7A5 (0.51) | ANPEPRNPEPDNPEPSLC1A3SLC1A2 | |
| SCHEMBL4989232 | 0.84 | ANPEP (0.41) | ANPEPRNPEPDNPEPCPB2SLC1A3 | |
| SCHEMBL4989853 | 0.84 | GRIK1 (0.40) | ANPEPCPB2HSP90AB1FOLH1ERAP2 | |
| SCHEMBL4989888 | 0.83 | SLC1A1 (0.35) | ANPEPRNPEPDNPEPCPB2SLC1A3 | |
| SCHEMBL4983912 | 0.83 | TDP1 (0.35) | ANPEPRNPEPDNPEPCPB2SLC1A3 | |
| SCHEMBL4987663 | 0.83 | GRN (0.38) | ANPEPRNPEPDNPEPCPB2 | |
| SCHEMBL4985333 | 0.82 | CPB2 (0.37) | ANPEPRNPEPDNPEPCPB2SLC1A3 | |
| SCHEMBL4983787 | 0.81 | LDHA (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | claimed |
| US-7388023-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-17 | — | — | US | disclosed |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | WANER-LAMBERT COMPANY LLC (US) | 2007-06-07 | — | — | US | disclosed |
| US-7179934-B2 | Amino acids with affinity for the α2δ-protein | WARNER-LAMBERT COMPANY LLC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-06-09 | — | — | US | disclosed |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | WARNER-LAMBERT COMPANY LLC | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124668-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, SCN1A, OPRD1 | ANPEP 750/4885RNPEP 1730/4885DNPEP 332/4885 |
| US-20070129550-A1 | AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN | SCN2A, OPRD1, SCN1A | ANPEP 691/4885RNPEP 1513/4885DNPEP 355/4885 |
| US-20050101643-A1 | Amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | ANPEP 644/4885RNPEP 1486/4885DNPEP 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.